Overview

Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) issued its FY2026 Annual Report on July 7, 2026, highlighting a revenue of ₹8,869 crore for the year. The company operates 17 global development and manufacturing facilities and serves customers in more than 100 countries, with approximately 66% of revenue derived from regulated markets.

Business Segments

  • Piramal Pharma Solutions (CDMO) contributed 55% of total revenue and continued to support over 500 global customers. The segment announced a US$90 million investment to expand sterile injectables and payload linker capabilities.
  • Piramal Critical Care maintained its No. 1 position in the US sevoflurane market, completed the acquisition of Kenalog, and now serves over 6,000 hospitals, surgical centres and clinics worldwide.
  • Piramal Consumer Healthcare generated ₹1,274 crore in revenue, launched 31 new products and SKUs, and its Power Brands line recorded 24% growth, representing 52% of the Consumer Healthcare segment’s revenue.

Quality and Compliance

During FY2026 the company completed 38 regulatory inspections, including three USFDA inspections, and sustained a zero Official Action Indicated (OAI) observation record across all USFDA inspections, underscoring robust quality systems.

Sustainability and Workforce

Piramal Pharma achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse‑gas emissions compared with the FY2022 baseline, following approval of its science‑based decarbonisation roadmap. The workforce comprised over 7,285 employees, and the company recorded zero fatalities for the fifth consecutive year, reflecting its people‑first culture.

Associate Companies

One associate, Abbvie Therapeutics India Private Limited, a joint venture with AbbVie, has emerged as a market leader in the ophthalmology therapy area in India. Piramal also holds a strategic minority investment in Yapan Bio Private Limited, which operates in biologics, bio‑therapeutics, and vaccine segments.

Forward‑Looking Statements

Chairperson Ms. Nandini Piramal described FY2026 as a transitional year shaped by external disruptions and business‑specific factors, noting that the company exited the year on a stronger note across its three businesses with improved execution and better visibility of future growth.